Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

28.20CHF
4:31pm GMT
Change (% chg)

CHF-1.05 (-3.59%)
Prev Close
CHF29.25
Open
CHF29.40
Day's High
CHF29.45
Day's Low
CHF27.95
Volume
22,852
Avg. Vol
72,754
52-wk High
CHF82.00
52-wk Low
CHF25.10

Chart for

About

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone... (more)

Overall

Beta: 0.77
Market Cap(Mil.): CHF237.58
Shares Outstanding(Mil.): 6.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor

* SANTHERA OBTAINS WORLDWIDE EXCLUSIVE LICENSE FROM POLYPHOR TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE CANDIDATE FOR CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Feb 2018

BRIEF-Santhera Launches U.S. Expanded Access Program With Idebenone For Patients With DMD

* SANTHERA LAUNCHES U.S. EXPANDED ACCESS PROGRAM WITH IDEBENONE FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

06 Feb 2018

BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million

* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE

29 Jan 2018

BRIEF-Santhera: Negative CHMP Opinion On Appeal For Authorization Of Raxone

* SANTHERA RECEIVES NEGATIVE CHMP OPINION ON APPEAL FOR AUTHORIZATION OF RAXONE® IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Jan 2018

BRIEF-Shares In Santhera Pharmaceuticals Holding AG Suspended From Trading Until Further Notice‍​

Jan 24 Shares In Santhera Pharmaceuticals Holding Ag are suspended from trading until further notice - Six Swiss Exchange said.

24 Jan 2018

BRIEF-Santhera: negative opinion from the CHMP for Raxone in DMD

* SANTHERA RECEIVES NEGATIVE OPINION FROM THE CHMP FOR ITS MARKETING AUTHORIZATION APPLICATION FOR RAXONE® IN DMD AND INTENDS TO APPEAL THIS OPINION

15 Sep 2017

BRIEF-Santhera Pharmaceuticals Holding H1 net loss widens to CHF 22.7 million

* ‍1H 2017 SALES OF CHF 10.9 MILLION, INCREASE OF 51% COMPARED TO 1H 2016​

05 Sep 2017

BRIEF-Santhera announces approval of Raxone for LHON in Israel

* SANTHERA ANNOUNCES APPROVAL OF RAXONE FOR LHON IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Aug 2017

Earnings vs. Estimates